Navigation Links
Arizona Judge Rejects Medtronic Inc.'s Efforts to Dismiss a Lawsuit That Alleges the Company Promoted Off-Label Use of Its Infuse Bone Graft Product, Parker Waichman LLP Reports
Date:8/26/2013

(PRWEB) August 26, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, notes that, according to court documents filed with the U.S. District Court, Arizona, on Aug. 21, 2013, U.S. District Judge G. Murray Snow rejected Medtronic Inc.'s arguments that federal law preempted a lawsuit trial built on claims that the company had promoted the off-label use of its Infuse bone graft product. According to the documents, Medtronic was seeking to have the complaint fully dismissed, alleging that all the Plaintiff’s claims were preempted by medical device amendments to the Food, Drug and Cosmetic Act, which furnishes the U.S. Food and Drug Administration (FDA) with extensive control over the manufacture and marketing of an FDA-approved medical device. (Ramirez v. Medtronic Inc. et al., Case No.:2:13-cv-00512). But Judge Snow found that federal law does not preempt most of the Plaintiff's claims.

“The majority of [the Plaintiff’s claims] trace her doctor’s off-label use of Infuse back to Medtronic’s off-label promotion and are therefore not preempted,” the judge wrote in the court documents.

Parker Waichman LLP continues to investigate allegations of people who claim they were harmed by the product. Such allegations are not limited to the off-label use of Medtronic’s Infuse. In fact, two independent studies* published in the June edition of the medical journal Annals of Internal Medicine call into question Infuse’s overall level of effectiveness, while also highlighting potential harm the product can cause.
(*http://annals.org/article.aspx?articleid=1696646; http://annals.org/article.aspx?articleid=1696645)

The two independent studies, overseen by Yale University, reveal important key findings regarding Medtronic’s Infuse product—namely, that there is little, if any, difference in the effectiveness of Infuse over a traditional bone graft. Additionally, Infuse has the potential to cause harmful, if not fatal, side effects, including:

  •     Retrograde ejaculation
  •     Cancer
  •     Pain
  •     Extraneous bone growth

Medtronic approached Yale University researchers after a June 2011 study published in The Spine Journal disclosed that Medtronic-paid researchers had failed to report serious potential complications from use of Infuse bone graft products in spinal surgery.

Infuse was approved by the FDA in 2002, explicitly for use in a single type of spinal surgery that involves fusing together vertebrae in the lower spine, with the surgeon using a frontal approach. But it became widely used off-label—meaning for uses not officially approved by the FDA. On July 8, 2008, the FDA issued a safety alert to warn about the use of Infuse in the upper spine and the neck region after receiving dozens of reports of serious side effects associated with such use of the device. Among the side effects stemming from off-label use of this device, according to the FDA, are:

  •     Swelling of neck and throat tissue, resulting in compression of the airway and/or neurological structures in the neck
  •     Difficulty swallowing, breathing or speaking
  •     Nerve damage
  •     Severe dysphagia

In the 2008 safety alert the FDA also noted that, since 2004, it had received nearly 40 reports of complications arising from the off-label use of Infuse in cervical spine fusion. The FDA highlighted the fact that “[w]hen airway complications occurred, medical intervention was frequently necessary. Treatments needed included respiratory support with intubation, anti-inflammatory medication, tracheotomies and, most commonly, second surgeries to drain the surgical site.”

Parker Waichman LLP is currently offering free legal consultations to victims of Medtronic Infuse Bone Graft Injuries. If you or a loved one suffered a serious complication or injury after receiving Medtronic Infuse, please contact their office by visiting the firm's Medtronic Infuse injury page at yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/medtronic_infuse_arizona/08/prweb11062998.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Snoring Isn't Sexy Member Dr. Mark Levy attends Academy of Clinical Sleep Disorders Disciplines Conference in Phoenix, Arizona
2. Arizona State University secures defense contract
3. 40,000 Arizona student athletes receive concussion tests from Mayo Clinic
4. Arizona Dental Heights Moves to Using the New Nomad Pro Hand Held X-Ray System
5. The Goodie Boxes - Providing Affordable Meals for Families begins Operations in the Phoenix, Scottsdale, Arizona Area
6. Copper Vista Dental Care LLC in Arizona Announces the Opening of its Globe Dental Office
7. Fitness 4 Home Superstore, Inc. Announces Nation’s Largest Online Retailer to Charge Arizona Residents Full Sales Tax Beginning February 1, 2013
8. Top Elliptical Machines in Arizona named by TopConsumerReviews.com
9. Dr. Lattie Coor to Discuss "The Arizona We Want" Initiative March 27 at Scottsdale Community College
10. Maricopa Community Colleges Provost Dr. Maria Harper-Marinick Named Among Arizona's Most Influential Executives
11. Arizona Assisted Living Placement Service Above and Beyond Is Offering New Promotion for Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... CA (PRWEB) , ... April 28, 2017 , ... ... pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians ... experience, since it streamlines the reporting process and provides a familiar interface that ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
(Date:4/28/2017)... York, NY (PRWEB) , ... April 28, 2017 ... ... Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. ... recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology: